1213360-40-7

Upstream product

• 61072-56-8 4-chloro-2-fluorobenzaldehyde 
• 1433401-94-5 (S)-2-methyl-propane-2-sulfinic acid [(R)-(4-chloro-2-fluoro-phenyl)-cyclopropyl-methyl]-amide 
• 856562-58-8 (S)-(-)-2-methylpropane-2-sulfinic acid 1-(4-chloro-2-fluorophenyl)(E)methylideneamide 

Downstream Products

• 1433402-10-8 [(R)-(4-chloro-2-fluoro-phenyl)-cyclopropyl-methyl]-carbamic acid tert-butyl ester 
• 1433404-96-6 tert-butyl N-[(R)-{3-[(4-{[(tert-butyldimethylsilyl)oxy]methyl}phenyl)carbonyl]-4-chloro-2-fluorophenyl}(cyclopropyl)methyl]carbamate 
• 1433403-85-0 tert-butyl N-[(R)-{3-[(6-aminopyridin-3-yl)carbonyl]-4-chloro-2-fluorophenyl}(cyclopropyl)methyl]carbamate 
• 1433403-77-0 tert-butyl N-[(R)-{3-[(6-bromopyridin-3-yl)carbonyl]-4-chloro-2-fluorophenyl}(cyclopropyl)methyl]carbamate 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOUNDS

The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections. The compounds have the formula (1): or a salt, N-oxide, tautomer or stereoisomer thereof, wherein A is CH or N; E is CH or N; R1 is selecte

SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION

The invention provides compounds of the formula (I): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF or nitrogen; and R0 is hydrogen or C1-2 alkyl; R1a is selected from CONH2